Compare Adecoagro SA (AGRO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adecoagro SA vs Merck & Co., Inc. — how do they compare? Adecoagro SA trades at $10.2 (market cap $1.39B), while Merck & Co., Inc. trades at $126.47 (market cap $318.26B). The key difference: Merck & Co., Inc. is far larger — about 229× Adecoagro SA's market cap, and Adecoagro SA pays the higher dividend (3.08%). Which is the better fit depends on your goals.
| AGRO | MRK | |
|---|---|---|
Market Cap | $1.39B | $318.26B |
Sector | Technology | Health |
52-Week High | $15.25 | $129.52 |
52-Week Low | $7.13 | $77.60 |
Enterprise Value | $3.42B | $361.68B |
Dividend Yield | 3.08% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.48, down 1.66% today, with a bearish technical signal despite neutral oscillators. The company reported mixed quarterly results, missing Q1 2026 EPS estimates but showing strong adjusted EBITDA growth. Valuation metrics appear attractive with P/S of 0.71 and P/B of 0.78, though profitability remains weak with a 0.91% net margin. Recent news highlights innovation in agriculture operations and a declared $0.12 dividend for H1 2026.
The stock offers value appeal with below-market multiples and analyst consensus target of $12.75 implying 34% upside. However, inconsistent earnings performance and negative net income in 2025 pose execution risks. The bearish technical trend and competitive pressures in sustainable agriculture require careful monitoring for potential investors.
Merck (MRK) trades at $126.61, down slightly by 0.13% today, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported solid earnings beats in recent quarters, with Q1 2026 loss narrower than expected, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The stock offers upside to the consensus price target of $139.33, driven by earnings momentum and expansion in high-margin drugs, but faces risks from patent expirations, regulatory scrutiny, and integration challenges from acquisitions. Investors should weigh the strong analyst buy rating (67.57%) against potential volatility from macroeconomic and industry-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
